ArticleVaccines2024
Coverage with the First Dose of Human Papillomavirus Vaccination among Females Aged 9-50 Years in Shenzhen, China: A Surveillance Based on Administrative Health Records in 2023.
Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Real-world effectiveness of HPV vaccination against high-risk type HPV DNA positivity among adult women aged 18 - 45years in China: A matched test-negative design study.Human vaccines & immunotherapeutics · 2026Article
- Limited discriminant validity of health belief and 3C models in high HPV vaccine coverage settings: the moderating role ofFrontiers in public health · 2026Article
- Initial different human papillomavirus infection statuses and subsequent infection risk: a decade-long longitudinal study.Journal of health, population, and nutrition · 2025Article
- Associations of altruistic factors and perceptions with intention to receive Respiratory Syncytial Virus (RSV) vaccination among older adults in China.Human vaccines & immunotherapeutics · 2025Article
- HPV vaccination coverage, hesitancy, and barriers: Insights from a serial cross-sectional study in Shanghai, China (2019-2024).Human vaccines & immunotherapeutics · 2025Article
- The vaccination status and attitudes toward human papillomavirus among gynecologists in China: A cross-sectional survey.Human vaccines & immunotherapeutics · 2025Article
- Is the HPV vaccine lottery system equitable under constrained vaccine supply? A cross-sectional study in China.Archives of public health = Archives belges de sante publique · 2025Article
- Human papillomavirus vaccination willingness and influencing factors among women in China: A systematic review and meta-analysis.Preventive medicine reports · 2025Review
- Trends in HPV-positive cervical cancer prevalence: a retrospective study from 2013 to 2020.Virology journal · 2025Article
- Age-related distribution of human papillomavirus genotypes in women with cervical squamous cell carcinoma from Linyi, China, 2015-2023.Virology journal · 2025Article
- Article
- The cervical cancer related distribution, coinfection and risk of 15 HPV types in Baoan, Shenzhen, in 2017-2023.Virology journal · 2024Article
- Comparative study of triage strategies for women with atypical squamous cells of undetermined significance in the post-vaccine era.Frontiers in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
China started to offer human papillomavirus (HPV) vaccines to females aged 9-45 years in 2016. However, there was a lack of reports about HPV vaccination coverage in a representative sample of females in China. Therefore, this study aimed to examine the current HPV coverage and associated factors among females aged 9-50 years in Shenzhen, China, based on administrative health records kept by community health centers. A multistage random sampling approach was used. The research team randomly selected 18 community health centers in Shenzhen, and 3118 health records of females aged 9-50 years were then randomly selected from these health centers. Among all participants, 18.7% received at least one dose of HPV vaccination. The highest coverage was observed among females aged 18-26 years (23.4%), followed by those aged 27-35 years (22.0%) and 36-45 years (20.2%). Such coverage was very low among females aged 9-17 years (4.6%) and those aged 46-50 years (3.2%). Among females aged 18 years or above, higher education level, having a family doctor, and permanent residency in Shenzhen were associated with higher HPV vaccination coverage, while older age and being married/divorced were negatively associated with coverage. The HPV vaccination coverage in Shenzhen was 18.7% and there is a strong need for improvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.